Commonly used non-cancer medications, including antihypertensives, statins, metformin, and proton pump inhibitors, have been suggested to influence breast cancer outcomes, though large-scale evidence remains limited. To clarify these associations, a pooled individual participant data meta-analysis examined the impact of such concomitant medicines on survival and adverse events among 23,211 breast cancer patients across 19 clinical trials. The study found that proton pump inhibitor (PPI) use was associated with poorer overall survival (hazard ratio (HR) 1.19), progression-free survival (HR 1.11), and a higher risk of grade ≥3 adverse events (odds ratio (OR) 1.36).
Beta-blockers, ACE inhibitors/ARBs, and calcium channel blockers were linked to increased adverse event rates but showed no significant effect on survival outcomes. In contrast, statins and metformin exhibited no significant…
